Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2006

View Archived Issues

Trials reveal efficacy of Hylan G-F 20 in osteoarthritis

Various agents being tested for efficacy in Sjogren's syndrome

CoFactor begins phase III study in metastatic colorectal cancer

SBIR grant supports ArmaGen's development of AGT-140 for stroke

Oncolys Biopharma licenses Ed4T for HIV-1 from Yale University

Dosing under way in phase IIa nociceptive pain study of cannabinor

Eisai licenses SERMS to Radius Health

Nabi and Kedrion sign European agreement for Civacir

North American phase III study of Miraxion achieves target enrollment

Phase IIa study of oleoyl-estrone now dosing patients

Characterization of SPI-256 mutational escape pathways

deCODE files to begin phase I studies of DG-051 for heart attack prevention

Polyphenon E Ointment review extended

NDA submission for CIP-Tramadol ER

New KB-2115 formulation completes phase I study

Vertex enters into agreement for VX-950, begins initiative in HCV

New River files IND for NRP-409

NDA submission for Zensana Oral Spray

Epix files appeal over Vasovist approvable letters

RotaTeq approved in Europe

THRX-165724 tested in AML cell lines

HET-0016 shows efficacy in a rat brain tumor model

CHMP recommends Keppra monotherapy in epilepsy

European approval for Kaletra tablet

XY-8: Novel water-soluble camptothecin derivative active in preclinical tumor models

Novel norepinephrine and serotonin reuptake inhibitors imparted by Pfizer

Recent Abbott patent discloses novel vanilloid VR1 receptor antagonists

New antiinfective agents disclosed in recent patents

MS-560 demonstrates selectivity against matrix metalloproteinases involved in atherosclerosis

Promising preliminary results of phase I/II trial of ofatumumab in rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...